Vyvgart Crosses the Antibody Line in Seronegative Myasthenia Gravis
Episode Summary
Phase 3 ADAPT SERON data show efgartigimod improves function in seronegative generalized myasthenia gravis, with FDA priority review potentially expanding targeted treatment options for underserved patients.